Breaking Innovation Paralysis

Natalie Yeadon, Founder and CEO, Augmentios

Canada builds world-class cures and companies, then consistently loses them. Breaking Innovation Paralysis investigates why, through candid conversations with the founders, scientists, and policymakers living this reality every day. Host Natalie Yeadon, a former clinician, pharmaceutical executive, and tech entrepreneur who built and exited a global Canadian company, traces the problem to three forces: inertia, risk aversion, and diffusion of responsibility. Each episode goes inside a different layer of the system, from university labs to government policy, to find out how to fix.

Episodes

  1. Aug 3

    Canada Sold Insulin for $1 - Our $190 Billion Innovation Problem

    Welcome to the premiere episode of Breaking Innovation Paralysis, where we dive into the urgent need for change within Canada's health innovation ecosystem. A Bold Vision for Canada Natalie Yeadon opens the series with a powerful proposal from Dr. Kevin Smith, president and CEO of Toronto's University Health Network. He envisions Canada as the top destination for taking scientific discoveries to market. Yet, as Yeadon points out, Canada has a troubling history of failing to capitalize on its own innovations, citing the sad irony that while we take pride in discovering insulin, we import almost all of it today. "We sell the cheap ingredients... to foreign companies, and then we spend billions of dollars buying back the finished cake."— Natalie Yeadon This cycle highlights a deeper issue: Canada doesn't have an innovation deficit; it suffers from an institutional courage gap. Yeadon reflects on her experiences in clinical settings and the pharmaceutical industry, emphasizing that the real challenge lies in overcoming the fear of taking risks within our systems. The Three Biases of Innovation Paralysis Yeadon identifies three behavioral biases that contribute to this paralysis: Inertia: The tendency to stick to familiar methods, often at the expense of better, more efficient solutions.Diffusion of Responsibility: A fragmented system where accountability is unclear, leading to inaction.Bidirectional Risk Aversion: A culture that prioritizes avoiding blame over fostering innovation.These biases create a climate where innovation struggles to thrive, and as Yeadon argues, we must confront them head-on to foster a more dynamic healthcare environment. A Call to Action Yeadon's company, Augmentios, is conducting a comprehensive audit of Canada's health innovation pipeline, examining everything from university labs to patient care. The goal is to dismantle the psychological barriers that stifle innovation and implement actionable strategies to create a more effective healthcare system. "We're here to conduct a systematic, room-by-room audit of the entire Canadian health innovation pipeline."— Natalie Yeadon Through tools like pre-mortems, decision journaling, and safe-to-fail simulations, Augmentios seeks to empower healthcare leaders and innovators to embrace risk and creativity. Join the Movement As we continue to explore these critical themes throughout the season, we invite you to reflect on your own experiences within the healthcare system. If you have insights or stories to share, connect with us. Together, we can cultivate the institutional courage necessary to unlock Canada's full potential in health innovation. For more insights, visit Augmentios.com and stay tuned for upcoming episodes!

About

Canada builds world-class cures and companies, then consistently loses them. Breaking Innovation Paralysis investigates why, through candid conversations with the founders, scientists, and policymakers living this reality every day. Host Natalie Yeadon, a former clinician, pharmaceutical executive, and tech entrepreneur who built and exited a global Canadian company, traces the problem to three forces: inertia, risk aversion, and diffusion of responsibility. Each episode goes inside a different layer of the system, from university labs to government policy, to find out how to fix.